A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

596

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer ALK-positive
Non-Small Cell Lung Cancer c-Met Dependent
Non-Small Cell Lung Cancer ROS Marker Positive
Systemic Anaplastic Large-Cell Lymphoma
Advanced Malignancies Except Leukemia

Interventions

DRUG: PF-02341066
DRUG: Rifampin
DRUG: Itraconazole

Sponsor

Pfizer